Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Instagram Outage Disrupts Thousands of U.S. Users 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
BRISBANE, Calif., May 16, 2017 -- CUTERA (Nasdaq:CUTR), a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, announced the launch of truSculpt® 3D, the newest advancement in non-surgical body sculpting, offering up to 24 percent fat reduction in a single treatment.
truSculpt 3D utilizes a controlled, monopolar radio frequency (RF) technology at 2 MHz to deliver targeted, uniform heating of the subcutaneous adipose tissue to achieve what we believe to be the highest clinical efficacy in the shortest possible treatment time. Focusing on three specific characteristics – dimension, definition, and depth – truSculpt® 3D offers an optimized and customizable approach to body sculpting for most size areas, large or small.
As the handpiece glides along the surface of the body, the patient rests comfortably throughout the treatment. truSculpt 3D reaches the optimal therapeutic temperature at 2 minutes, and over the course of a one-hour session, up to four areas can be treated with no downtime.
“Our study focused on treating participants with a single treatment using the truSculpt 3D body sculpting system,” explained Amy Taub M.D., truSculpt 3D clinical investigator and Founder/Director of Advanced Dermatology, LLC. “As an objective measurement, we validated the change in fat thickness reduction by using controlled ultrasound imaging and photography. We found that the clinical outcomes in both ultrasound measurements and photography were consistent with other non-invasive body sculpting technologies.”
“We are aggressively investing our R&D resources in the body sculpting segment of the market and believe that truSculpt, with these critical modifications, will be an important contributor to our planned revenue growth,” said James Reinstein, President and CEO at Cutera. “We are pleased with the progress we have made with our truSculpt platform and are excited about our truSculpt 3D launch as well as the future enhancements we plan to integrate into our truSculpt platform in the second half of 2017.”
The truSculpt® 3D body sculpting system is being launched in all critical markets during the second quarter of 2017, with a full global launch to occur by the end of 2017.
For more information on truSculpt 3D visit www.cutera.com.
About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements regarding the long-term prospects and opportunities in the laser and other energy-based equipment aesthetic market, the Company’s ability to successfully develop and launch its truSculpt 3D product and applications, expand its market share of the body sculpting market and derive significant incremental revenue from the truSculpt product, are forward-looking statements within the meaning of the Safe Harbor. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. Potential risks and uncertainties and other risk factors are described in the section entitled, “Risk Factors” in the Company’s most recent Form 10-Q as filed with the Securities and Exchange Commission on May 1, 2017. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
Contacts Media: Irwin Gail: 646-722-3299 Jessica Goldberg: [email protected] Alli Good: [email protected] Investor Relations John Mills Integrated Corporate Relations, Inc. 646-277-1254 [email protected]
